A phase II evaluation of liposomal doxorubicin (Doxil) in the treatment of persistent or recurrent squamous cell carcinoma of the cervix

Trial Profile

A phase II evaluation of liposomal doxorubicin (Doxil) in the treatment of persistent or recurrent squamous cell carcinoma of the cervix

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 13 Jun 2007 Status changed from in progress to completed.
    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top